Companies To Watch: eXIthera

The name of this company, eXIthera, refers to its therapeutic aim, inhibiting Factor XIa, a new target that may offer a way to avoid the bleeding problems with current anticoagulants. Its lead drug, an injectable coded EP-7041, has completed a Phase 1 clinical trial in healthy human subjects and moved to a program in cardiac […]

Overcoming The Hurdles of Starting up a Biopharmaceutical Company

Every emerging biopharmaceutical company has an interesting story that describes how they overcame major startup challenges, including study design, funding, and drug targeting strategies. eXIthera is developing a small molecule, EP-7041, to control the blood-clotting pathway and enable healthy blood flow without the concerns of adverse clotting or major bleeding via selective inhibition of Factor […]

eXIthera CEO, Dr. Neil Hayward, is featured on the Cutting Edge Cast

eXIthera is doing big things with small molecules. This clinical-stage biotech company is developing therapies to maintain the balance between healthy blood flow and clotting, specifically during heart surgery. In today’s Cutting Edge Cast, eXIthera CEO Neil Hayward, Ph.D., explains why this therapy is critical for patients.

Cream of the clotbusters? eXIthera ‘teas’ off at AHA with strong Phase I data

eXIthera Pharmaceuticals Inc. CEO Neil Hayward told BioWorld he's hoping to build a "continuum of care" around factor XIa inhibitor EP-7041, after Phase I data showed the intravenous (I.V.) version of the antithrombotic safe and well-tolerated in healthy volunteers after single or multiple ascending intravenous doses – and even turned up some clues to efficacy.